# Acromegaly Combination Treatment Study

> **NCT01538966** · NA · TERMINATED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 76 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Pegvisomant
- **DRUG:** Octreotide LAR
- **DRUG:** Lanreotide

## Key facts

- **NCT ID:** NCT01538966
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03-29
- **Primary completion:** 2022-05-20
- **Final completion:** 2022-05-20
- **Target enrollment:** 76 (ACTUAL)
- **Why stopped:** Review of the 12-month data showed patients who deviated from protocol with full IRB monitoring and reporting could not be optimally analyzed. Reopening the study for new enrollment is not feasible and the study was terminated with IRB approval.
- **Last updated:** 2023-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01538966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01538966, "Acromegaly Combination Treatment Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01538966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*